Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next DecadeBenzinga • 08/14/25
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?Zacks Investment Research • 08/12/25
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy AdoptionZacks Investment Research • 08/05/25
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/04/25
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsGlobeNewsWire • 08/04/25
Should You Invest in CRISPR Therapeutics (CRSP) Based on Bullish Wall Street Views?Zacks Investment Research • 07/30/25
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/28/25
Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something BigSeeking Alpha • 07/23/25
Nearly 89% of Companies are Seeing Insider Selling, But these 3 are Seeing Substantial Buying24/7 Wall Street • 07/22/25
Is It Worth Investing in CRISPR Therapeutics (CRSP) Based on Wall Street's Bullish Views?Zacks Investment Research • 07/14/25
CRISPR Therapeutics (CRSP) Moves 9.6% Higher: Will This Strength Last?Zacks Investment Research • 07/10/25
Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?Zacks Investment Research • 06/27/25
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular PipelineGlobeNewsWire • 06/26/25
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?Zacks Investment Research • 06/25/25
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street AnalystsThe Motley Fool • 06/21/25